Drugs / Y-90 ibritumomab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01234766 | Oct 2010 → Jan 2021 | follicular lymphoma | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Y-90 ibritumomab | “Y-90 ibritumomab” NCT01234766 ↗ |
| Known as | Zevalin | “90-yttrium(Y) ibritumomab tiuxetan (Zevalin) radioimmunotherapy” NCT01234766 ↗ |
| Route | Intravenous | “IV - Within 4 hours of rituximab, give over 10 minutes” NCT01234766 ↗ |